Verona Pharma plc

Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.